194 related articles for article (PubMed ID: 28060954)
1. Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis.
Lu M; Zessin AS; Glover W; Hsu DS
PLoS One; 2017; 12(1):e0169439. PubMed ID: 28060954
[TBL] [Abstract][Full Text] [Related]
2. Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin.
Bommer UA; Vine KL; Puri P; Engel M; Belfiore L; Fildes K; Batterham M; Lochhead A; Aghmesheh M
Cell Commun Signal; 2017 Feb; 15(1):9. PubMed ID: 28143584
[TBL] [Abstract][Full Text] [Related]
3. Synergistic inhibitory effects on hepatocellular carcinoma with recombinant human adenovirus Aspp2 and oxaliplatin via p53-independent pathway in vitro and in vivo.
Liu X; Xu J; Wang S; Yu X; Kou B; Chai M; Zang Y; Chen D
Int J Oncol; 2017 Oct; 51(4):1291-1299. PubMed ID: 28902369
[TBL] [Abstract][Full Text] [Related]
4. N-myc downstream-regulated gene 1 promotes oxaliplatin-triggered apoptosis in colorectal cancer cells via enhancing the ubiquitination of Bcl-2.
Yang X; Zhu F; Yu C; Lu J; Zhang L; Lv Y; Sun J; Zheng M
Oncotarget; 2017 Jul; 8(29):47709-47724. PubMed ID: 28537875
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis.
Lu YX; Ju HQ; Wang F; Chen LZ; Wu QN; Sheng H; Mo HY; Pan ZZ; Xie D; Kang TB; Chen G; Yun JP; Zeng ZL; Xu RH
Cancer Lett; 2016 Sep; 380(1):87-97. PubMed ID: 27322737
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.
Perez M; Lucena-Cacace A; Marín-Gómez LM; Padillo-Ruiz J; Robles-Frias MJ; Saez C; Garcia-Carbonero R; Carnero A
Oncotarget; 2016 May; 7(22):33111-24. PubMed ID: 27105527
[TBL] [Abstract][Full Text] [Related]
9. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
Chian S; Li YY; Wang XJ; Tang XW
Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
[TBL] [Abstract][Full Text] [Related]
11. Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer.
Shan J; Xuan Y; Zhang Q; Zhu C; Liu Z; Zhang S
Protein Cell; 2016 Aug; 7(8):571-85. PubMed ID: 27472952
[TBL] [Abstract][Full Text] [Related]
12. Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer.
Chen ZH; Qi JJ; Wu QN; Lu JH; Liu ZX; Wang Y; Hu PS; Li T; Lin JF; Wu XY; Miao L; Zeng ZL; Xie D; Ju HQ; Xu RH; Wang F
J Exp Clin Cancer Res; 2019 May; 38(1):196. PubMed ID: 31088567
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
14. Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.
Gaur S; Chen L; Ann V; Lin WC; Wang Y; Chang VH; Hsu NY; Shia HS; Yen Y
Mol Cancer; 2014 Feb; 13():21. PubMed ID: 24495750
[TBL] [Abstract][Full Text] [Related]
15. In Vivo Delivery and Therapeutic Effects of a MicroRNA on Colorectal Liver Metastases.
Oshima G; Guo N; He C; Stack ME; Poon C; Uppal A; Wightman SC; Parekh A; Skowron KB; Posner MC; Lin W; Khodarev NN; Weichselbaum RR
Mol Ther; 2017 Jul; 25(7):1588-1595. PubMed ID: 28457664
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor effects of endostar in combination with oxaliplatin via inhibition of HIF and CXCR4 in the colorectal cell line SW1116.
Jin F; Ji H; Jia C; Brockmeier U; Hermann DM; Metzen E; Zhu Y; Chi B
PLoS One; 2012; 7(10):e47161. PubMed ID: 23071744
[TBL] [Abstract][Full Text] [Related]
17. PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer.
Zhang Y; Wang X; Qin X; Wang X; Liu F; White E; Zheng XF
EBioMedicine; 2015 Dec; 2(12):1944-56. PubMed ID: 26844273
[TBL] [Abstract][Full Text] [Related]
18. Transforming Growth Factor β Mediates Drug Resistance by Regulating the Expression of Pyruvate Dehydrogenase Kinase 4 in Colorectal Cancer.
Zhang Y; Zhang Y; Geng L; Yi H; Huo W; Talmon G; Kim YC; Wang SM; Wang J
J Biol Chem; 2016 Aug; 291(33):17405-16. PubMed ID: 27330076
[TBL] [Abstract][Full Text] [Related]
19. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
[TBL] [Abstract][Full Text] [Related]
20. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.
Ning Y; Labonte MJ; Zhang W; Bohanes PO; Gerger A; Yang D; Benhaim L; Paez D; Rosenberg DO; Nagulapalli Venkata KC; Louie SG; Petasis NA; Ladner RD; Lenz HJ
Mol Cancer Ther; 2012 Jun; 11(6):1353-64. PubMed ID: 22391039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
